Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure
- PMID: 1268491
- PMCID: PMC1639291
- DOI: 10.1136/bmj.1.6015.939
Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure
Abstract
Plasma concentrations of lignocaine were measured during and after infusion of lignocaine at 1.4 mg/min for 36-46 hours in 12 patients with myocardial infarction and one patient with cardiac failure due to uncontrolled ventricular tachycardia. In six patients without cardiac failure the plasma concentrations of lignocaine rose progressively during the infusion and the mean lignocaine half life was 4.3 hours compared with 1.4 hours in healthy subjects. Mean plasma lignocaine concentrations were significantly higher in seven patients with cardiac failure, and concentrations also rose during the infusion and the half life was considerably prolonged to 10.2 hours. Lignocaine concentrations rose rapidly to toxic levels when cardiogenic shock developed in one patient and did not fall when the infusion was stopped. The mean plasma antipyrine half life was moderately prolonged (19.4 hours) in a larger group of patients with myocardial infarction and cardiac failure but returned to normal during convalescence (13.2 hours). The metabolism of lignocaine is grossly abnormal in patients with cardiac failure and cardiogenic shock after myocardial infarction.
Similar articles
-
Clinical pharmacokinetics of lignocaine.Clin Pharmacokinet. 1978 May-Jun;3(3):177-201. doi: 10.2165/00003088-197803030-00001. Clin Pharmacokinet. 1978. PMID: 350470 Review.
-
Lignocaine and indocyanine green kinetics in patients following myocardial infarction.Br J Clin Pharmacol. 1980 Oct;10(4):353-61. doi: 10.1111/j.1365-2125.1980.tb01771.x. Br J Clin Pharmacol. 1980. PMID: 7448106 Free PMC article.
-
Factors affecting free (unbound) lignocaine concentration in suspected acute myocardial infarction.Br J Clin Pharmacol. 1989 Nov;28(5):593-7. doi: 10.1111/j.1365-2125.1989.tb03547.x. Br J Clin Pharmacol. 1989. PMID: 2590613 Free PMC article.
-
Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease.Br Med J. 1977 May 28;1(6073):1384-7. doi: 10.1136/bmj.1.6073.1384. Br Med J. 1977. PMID: 861646 Free PMC article.
-
The pharmacokinetics of lignocaine and beta-adrenoceptor antagonists in patients with acute myocardial infarction.Clin Pharmacokinet. 1987 Nov;13(5):293-316. doi: 10.2165/00003088-198713050-00002. Clin Pharmacokinet. 1987. PMID: 2891461 Review.
Cited by
-
Prophylaxis of primary ventricular fibrillation in acute myocardial infarction. The case against lignocaine.Br Heart J. 1984 Sep;52(3):241-7. doi: 10.1136/hrt.52.3.241. Br Heart J. 1984. PMID: 6380549 Free PMC article. Clinical Trial. No abstract available.
-
Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits.Br J Pharmacol. 1994 Sep;113(1):317-23. doi: 10.1111/j.1476-5381.1994.tb16211.x. Br J Pharmacol. 1994. PMID: 7812627 Free PMC article.
-
Clinical pharmacokinetics of lignocaine.Clin Pharmacokinet. 1978 May-Jun;3(3):177-201. doi: 10.2165/00003088-197803030-00001. Clin Pharmacokinet. 1978. PMID: 350470 Review.
-
Drug kinetics and hepatic blood flow.Clin Pharmacokinet. 1979 Nov-Dec;4(6):433-48. doi: 10.2165/00003088-197904060-00003. Clin Pharmacokinet. 1979. PMID: 391463 Review. No abstract available.
-
Free drug concentration monitoring in clinical practice. Rationale and current status.Clin Pharmacokinet. 1986 Nov-Dec;11(6):450-69. doi: 10.2165/00003088-198611060-00003. Clin Pharmacokinet. 1986. PMID: 3542337 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources